~ Buy the VTAMA (tapinarof) Drug Profile, 2024 PDF Report in the Report Store ~

VTAMA Drug Patent Profile

✉ Email this page to a colleague

When do Vtama patents expire, and when can generic versions of Vtama launch?

Vtama is a drug marketed by Dermavant Sci and is included in one NDA. There are nine patents protecting this drug.

This drug has seventy-two patent family members in thirty-six countries.

The generic ingredient in VTAMA is tapinarof. One supplier is listed for this compound. Additional details are available on the tapinarof profile page.

DrugPatentWatch^® Generic Entry Outlook for Vtama

Vtama will be eligible for patent challenges on May 23, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 13, 2038. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for VTAMA?
What are the global sales for VTAMA?
What is Average Wholesale Price for VTAMA?

Summary for VTAMA

International Patents:	72
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	60
Patent Applications:	88
Drug Prices:	Drug price information for VTAMA
What excipients (inactive ingredients) are in VTAMA?	VTAMA excipients list
DailyMed Link:	VTAMA at DailyMed

Drug patent expirations by year for VTAMA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VTAMA

Generic Entry Date for VTAMA^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: ⤷ Sign Up NDA: 215272 Dosage: CREAM;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for VTAMA

Drug Class	Aryl Hydrocarbon Receptor Agonist
Mechanism of Action	Aryl Hydrocarbon Receptor Agonists

US Patents and Regulatory Information for VTAMA

VTAMA is protected by nine US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VTAMA is ⤷ Sign Up.

This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VTAMA

Topical pharmaceutical compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Topical pharmaceutical compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS

Process for preparing tapinarof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

FDA Regulatory Exclusivity protecting VTAMA

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dermavant Sci	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Dermavant Sci	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Dermavant Sci	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up		Y		⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for VTAMA

When does loss-of-exclusivity occur for VTAMA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 18365241
Patent: Process for preparing tapinarof
Estimated Expiration: ⤷ Sign Up

Patent: 23274224
Patent: PROCESS FOR PREPARING TAPINAROF
Estimated Expiration: ⤷ Sign Up

Brazil

Patent: 2020009158
Patent: processo para o preparo de um composto, composto e composição farmacêutica
Estimated Expiration: ⤷ Sign Up

Canada

Patent: 82115
Patent: PROCESSUS POUR LA PREPARATION DE TAPINAROF (PROCESS FOR PREPARING TAPINAROF)
Estimated Expiration: ⤷ Sign Up

Chile

Patent: 20001226
Patent: Proceso para preparar tapinarof.
Estimated Expiration: ⤷ Sign Up

Patent: 23000154
Patent: Proceso para preparar tapinarof; compuestos intermediarios; solvato de tapinarof; forma cristalina y composición farmacéutica que la comprende (sol. div. 202001226).
Estimated Expiration: ⤷ Sign Up

China

Patent: 1511357
Patent: PROCESS FOR PREPARING TAPINAROF
Estimated Expiration: ⤷ Sign Up

Colombia

Patent: 20007018
Patent: Proceso para preparar tapinarof
Estimated Expiration: ⤷ Sign Up

European Patent Office

Patent: 06725
Patent: PROCESSUS POUR LA PRÉPARATION DE TAPINAROF (PROCESS FOR PREPARING TAPINAROF)
Estimated Expiration: ⤷ Sign Up

Israel

Patent: 4439
Patent: תהליך להכנת טפינארוף (Process for preparing tapinarof)
Estimated Expiration: ⤷ Sign Up

Patent: 4090
Patent: תהליך להכנת טפינארוף (Process for preparing tapinarof)
Estimated Expiration: ⤷ Sign Up

Japan

Patent: 12664
Estimated Expiration: ⤷ Sign Up

Patent: 66399
Estimated Expiration: ⤷ Sign Up

Patent: 21063100
Patent: タピナロフを調製するためのプロセス (PROCESS FOR PREPARING TAPINAROF)
Estimated Expiration: ⤷ Sign Up

Patent: 21169482
Patent: タピナロフを調製するためのプロセス (PROCESS FOR PREPARING TAPINAROF)
Estimated Expiration: ⤷ Sign Up

Patent: 21502333
Patent: タピナロフを調製するためのプロセス
Estimated Expiration: ⤷ Sign Up

Patent: 23002516
Patent: タピナロフを調製するためのプロセス
Estimated Expiration: ⤷ Sign Up

Patent: 24069233
Patent: タピナロフを調製するためのプロセス (PROCESS FOR PREPARING TAPINAROF)
Estimated Expiration: ⤷ Sign Up

Mexico

Patent: 20004785
Patent: PROCESO PARA PREPARAR TAPINAROF. (PROCESS FOR PREPARING TAPINAROF.)
Estimated Expiration: ⤷ Sign Up

Patent: 22015106
Patent: PROCESO PARA PREPARAR TAPINAROF. (PROCESS FOR PREPARING TAPINAROF.)
Estimated Expiration: ⤷ Sign Up

Russian Federation

Patent: 20116424
Patent: СПОСОБ ПОЛУЧЕНИЯ ТАПИНАРОФА
Estimated Expiration: ⤷ Sign Up

Singapore

Patent: 202002576T
Patent: PROCESS FOR PREPARING TAPINAROF
Estimated Expiration: ⤷ Sign Up

South Korea

Patent: 200087786
Patent: 타피나로프의 제조 방법
Estimated Expiration: ⤷ Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VTAMA around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
South Africa	202007965	TOPICAL PHARMACEUTICAL COMPOSITIONS	⤷ Sign Up
Dominican Republic	P2017000270	COMPOSICIONES FARMACÉUTICAS TÓPICAS	⤷ Sign Up
Brazil	112017024934	composições farmacêuticas tópicas	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Indicators of Generic Entry

AI Research Assistant

Questions you can ask:

Summary for VTAMA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VTAMA

Pharmacology for VTAMA

Patents protecting VTAMA

FDA Regulatory Exclusivity protecting VTAMA

When does loss-of-exclusivity occur for VTAMA?

Make Better Decisions: Try a trial or see plans & pricing

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VTAMA